JPH04299992A - Produciton of antibody - Google Patents

Produciton of antibody

Info

Publication number
JPH04299992A
JPH04299992A JP3064843A JP6484391A JPH04299992A JP H04299992 A JPH04299992 A JP H04299992A JP 3064843 A JP3064843 A JP 3064843A JP 6484391 A JP6484391 A JP 6484391A JP H04299992 A JPH04299992 A JP H04299992A
Authority
JP
Japan
Prior art keywords
culture
antibody
carbon dioxide
cells
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP3064843A
Other languages
Japanese (ja)
Inventor
Shinichiro Haji
信一郎 土師
Masako Tsukino
月野 雅子
Satoshi Amano
聡 天野
Chinatsu Asamatsu
浅松 千夏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP3064843A priority Critical patent/JPH04299992A/en
Publication of JPH04299992A publication Critical patent/JPH04299992A/en
Withdrawn legal-status Critical Current

Links

Abstract

PURPOSE:To provide a process for the production of an antibody suitable for the production of antibody by cell culture and having improved production efficiency. CONSTITUTION:The subject cell-culture process for the production of antibody is characterized by the control of the culture temperature to 29-36 deg.C which is lower than the standardized conventional culture temperature (37 deg.C). The yield of antibody is remarkably increased simply by controlling the culture temperature within the above range.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明は、細胞培養法による抗体
の製造方法に関する。より詳細には、本発明は細胞の培
養に際して培養温度を一定温度に制御することによる収
率のよい抗体の製造方法に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing antibodies by cell culture. More specifically, the present invention relates to a method for producing antibodies with good yield by controlling the culture temperature to a constant temperature during cell culture.

【0002】0002

【従来の技術】抗体は、各種診断薬、医薬品として需要
が増加しており、安価で簡便な製造方法の開発が求めら
れている。この要求を満たすべく細胞培養法による抗体
の製造方法が検討されており、無血清培地の開発、潅流
培養、漉過培養など培養方法の開発、種々の培養装置の
開発が行われている。(例えば、新生化学実験講座、第
18巻、細胞培養技術、日本生化学会編;BIOTEC
HNOLOGY, Vol.6b, 249 ページH
.J.Rehm編、を参照)動物細胞培養においては、
培養条件として培養温度37℃、培養装置内の炭酸ガス
濃度5%が広く画一的に用いられており、抗体の収量と
培養温度、炭酸ガス濃度の関係に着目した例は従来技術
文献に未載である。
BACKGROUND OF THE INVENTION Antibodies are in increasing demand as various diagnostic agents and pharmaceuticals, and there is a need for the development of inexpensive and simple manufacturing methods. In order to meet this demand, methods for producing antibodies using cell culture methods are being considered, and development of culture methods such as serum-free media, perfusion culture, and strain culture, and various culture devices are being developed. (For example, New Biochemistry Experiment Course, Volume 18, Cell Culture Technology, edited by the Japanese Biochemical Society; BIOTEC
HNOLOGY, Vol. 6b, 249 page H
.. J. (Rehm, ed.) In animal cell culture,
As culture conditions, a culture temperature of 37°C and a carbon dioxide concentration of 5% in the culture apparatus are widely and uniformly used, and there are no examples in the prior art literature that focus on the relationship between antibody yield, culture temperature, and carbon dioxide concentration. It is listed.

【0003】0003

【発明が解決しようとする課題】従来の抗体製造方法は
一応の目的を達成しているとはいえ、いまだ改良の余地
があり、細胞培養法による抗体製造の生産性を向上すべ
く、さらなる改良を加えた製造方法を提供する必要性は
現在も依然として存在する。そこで、本発明の目的は、
細胞培養法による抗体製造に適した培養条件を開示し、
より効率のよい抗体の製造方法を提供することにある。
[Problems to be Solved by the Invention] Although conventional antibody production methods have achieved their intended purpose, there is still room for improvement, and further improvements are needed to improve the productivity of antibody production using cell culture methods. There continues to be a need to provide a manufacturing method that includes the following: Therefore, the purpose of the present invention is to
Disclose culture conditions suitable for antibody production by cell culture method,
The purpose of the present invention is to provide a more efficient method for producing antibodies.

【0004】0004

【課題を解決するための手段】本発明者らは、細胞培養
法による抗体製造の生産性を向上させるべく、鋭意研究
を重ねた結果、従来見逃されていた培養温度および培養
装置内の炭酸ガス濃度が抗体の収量に大きく影響を及ぼ
す要因であることを見いだした。その上、それらの条件
を一定の範囲内に制御することによって、抗体が予想外
の高収率で得られることを確認して本発明を完成した。 すなわち、上記課題は、本発明の抗体産生能を有する細
胞を栄養培地で培養して培養物から抗体を回収する抗体
の製造方法であって、培養温度を29℃から36℃の範
囲内に制御することを含んでなる方法によって解決でき
る。
[Means for Solving the Problems] As a result of extensive research in order to improve the productivity of antibody production using cell culture methods, the present inventors have discovered that the culture temperature and carbon dioxide gas in the culture apparatus, which had been overlooked in the past, We found that concentration is a factor that greatly influences antibody yield. Furthermore, the present invention was completed by confirming that antibodies can be obtained in unexpectedly high yields by controlling these conditions within a certain range. That is, the above-mentioned problem is a method for producing antibodies in which cells capable of producing the antibody of the present invention are cultured in a nutrient medium and antibodies are recovered from the culture, and the culture temperature is controlled within the range of 29°C to 36°C. This can be solved by a method that includes:

【0005】以下、本発明を具体的に説明する。本発明
の方法は、従来既知の細胞培養法に普遍的に用いること
ができ、本発明の制御された培養条件下で所期の効果が
得られる限り、以下により詳細に説明する抗体産生能を
有する細胞、栄養培地などそれ自体公知のものを用いる
ことができる。
[0005] The present invention will be explained in detail below. The method of the present invention can be universally used in conventionally known cell culture methods, and as long as the desired effect is obtained under the controlled culture conditions of the present invention, the antibody production ability described in more detail below can be improved. Cells and nutrient media known per se can be used.

【0006】本発明で用いる抗体産生能を有する細胞と
しては、一般に実施されている方法(例えば、単クロー
ン抗体  岩崎辰夫他著、を参照)により免疫動物から
取り出した抗体産性細胞、抗体産生細胞とミエローマ細
胞を細胞融合したハイブリドーマ細胞などのいずれも、
利用することができる。栄養培地としては、当該技術分
野で既知の細胞培養用培地をそのまま、あるいは培養す
る細胞の特質に応じて改変した培地を利用することがで
きる。これらの培地は、従来の技術文献に記載されてお
り、それらの幾つかは市販されているのでそれらをその
まま用いてもよい。好ましいものとしては、例えば、ダ
ルベコ変法イーグル培地、RPMI1640培地(以上
、ギブコ社)、ASF103培地、ASF104培地(
以上、味の素社)などが挙げられる。
[0006] Cells capable of producing antibodies used in the present invention include antibody-producing cells and antibody-producing cells extracted from immunized animals using commonly practiced methods (for example, see Monoclonal Antibodies by Tatsuo Iwasaki et al.). Both hybridoma cells, which are a cell fusion of myeloma cells and myeloma cells,
can be used. As the nutrient medium, a cell culture medium known in the art can be used as it is, or a medium modified according to the characteristics of the cells to be cultured. These media are described in conventional technical literature, and some of them are commercially available and may be used as is. Preferred examples include Dulbecco's modified Eagle's medium, RPMI1640 medium (Gibco), ASF103 medium, ASF104 medium (
Examples include Ajinomoto Co.).

【0007】このような細胞および栄養培地を用いる細
胞培養法を実施するに際し、本発明では、特に、培養温
度および必要により培養雰囲気下の炭酸ガス濃度を制御
する。かかる培養温度の設定は、上述のような従来画一
的に使用されてきた温度の37℃より低い温度であって
、特に29℃から36℃の範囲内に制御することが必須
である。また、培養雰囲気下の炭酸ガス濃度も従来画一
的に使用されてきた濃度である5%より低濃度、例えば
、3%付近に至適濃度が存在するが、本発明はこのよう
な濃度に限定されることなくその効果を奏する。すなわ
ち、炭酸ガス濃度が3%から7%の範囲内にあれば所期
の効果が得られる。なお、ここで培養雰囲気下の炭酸ガ
ス濃度とは、培養装置(または培養槽)内の炭酸ガス濃
度をいう。
[0007] When performing a cell culture method using such cells and a nutrient medium, the present invention particularly controls the culture temperature and, if necessary, the carbon dioxide concentration in the culture atmosphere. It is essential to set the culture temperature at a temperature lower than 37°C, which has conventionally been uniformly used as described above, and in particular, to control it within the range of 29°C to 36°C. Furthermore, the carbon dioxide concentration in the culture atmosphere is lower than the conventionally uniformly used concentration of 5%, for example, an optimum concentration exists around 3%. The effect is achieved without any limitations. That is, the desired effect can be obtained if the carbon dioxide concentration is within the range of 3% to 7%. Note that the carbon dioxide concentration under the culture atmosphere here refers to the carbon dioxide concentration within the culture apparatus (or culture tank).

【0008】以上のような培養条件の制御を行う手段と
しては、培養温度および培養液が接している気相中(培
養装置内)の炭酸ガス濃度を適当な方法により制御でき
るものであればいかなる方式の培養装置でもよい。限定
されるものでないが、具体的な培養装置としては、組織
培養フラスコ、スピンナーフラスコ、マルチトレイなど
と炭酸ガス培養装置、ジャーファーメンター、ホローフ
ァイバー型培養装置などが利用できる。
[0008] As a means for controlling the culture conditions as described above, any suitable method can be used as long as the culture temperature and the carbon dioxide concentration in the gas phase (inside the culture apparatus) in contact with the culture solution can be controlled. A type of culture device may also be used. Specific culture apparatuses that can be used include, but are not limited to, tissue culture flasks, spinner flasks, multi-trays, carbon dioxide gas culture apparatuses, jar fermenters, hollow fiber type culture apparatuses, and the like.

【0009】こうして一定時間培養して産生する抗体は
、ポリクローナルであってもモノクローナルであっても
よい。産生した抗体の培養物からの回収は、抗体の諸性
質を利用して一般に用いられている蛋白質の分離精製法
を適宜応用すればよい。例えば、培養液から細胞を遠心
分離除去し、硫酸アンモニウムにより抗体を濃縮、粗分
画し、透析脱塩後、各種クロマトグラフィーを用いて精
製することにより純度の高い抗体を取得することができ
る。
[0009] The antibodies thus produced by culturing for a certain period of time may be polyclonal or monoclonal. The produced antibodies can be recovered from the culture by appropriately applying commonly used protein separation and purification methods that take advantage of the various properties of antibodies. For example, highly pure antibodies can be obtained by removing cells from the culture medium by centrifugation, concentrating the antibodies with ammonium sulfate, crudely fractionating them, desalting them by dialysis, and purifying them using various types of chromatography.

【0010】0010

【実施例】以下、本発明をヒトIV型コラーゲンに対す
るモノクローナル抗体産生能を有するハイブリドーマ細
胞の培養を通してより具体的に説明するが、本発明の範
囲をこれらに限定することを意図するものでない。 実施例1  抗体産生細胞の調製 特開昭63−78067号および同63−246396
号公報に記載の方法に従って、ヒトIV型コラーゲンで
免疫したBALB/Cマウスから得た脾細胞とマウスミ
エローマ細胞SP2/Oから、ヒトIV型コラーゲンに
対するモノクローナル抗体JK−199(免疫グロブリ
ンクラスIgG2a)を産生するマウスハイブリドーマ
細胞を形成、次いで選択して JK199株とした。 
JK199株は、培地への血清添加濃度を逓減して継代
培養することにより、最終的に無血清培地ASF104
培地(味の素社製)に馴化させることが可能であった。 実施例2  抗体収量に対する培養温度の影響液体窒素
細胞保存器中で保存していた JK199株を解凍し、
この細胞をASF104培地にポリペプトンS(大五栄
養化学社製)を0.3%濃度添加した培地50mLを入
れた75cm2 組織培養フラスコ(コースター社)に
細胞濃度が約105 個/mlとなるように接種し、温
度を37℃、炭酸ガス濃度を5%に維持した炭酸ガス培
養装置内で静置培養した。3日間培養後、この種培養物
を、上記培地45mLを入れた75cm2 組織培養フ
ラスコ8個にそれぞれ5mLずつ接種し、培養温度をそ
れぞれ28℃、31℃、34℃、37℃、40℃に維持
した炭酸ガス培養装置内に2個ずつ静置して培養した。 装置内炭酸ガス濃度はすべて5%とした。14日間培養
後、培養液中の総細胞数を血球計数板で計数した。培養
液中の抗体濃度は、ヒトIV型コラーゲンをコーティン
グしたマイクロプレート、ビオチン化抗マウスIgG2
a抗体、アビジンパーオキシダーゼ、及び発色基質を用
いた酵素標識免疫定量法により測定した。各培養温度に
制御した培養結果を表1に示す。抗体濃度は培養温度が
37℃の場合を 100とした相対値で示す。
EXAMPLES The present invention will be explained in more detail below through the cultivation of hybridoma cells capable of producing monoclonal antibodies against human type IV collagen, but the scope of the present invention is not intended to be limited thereto. Example 1 Preparation of antibody-producing cells JP-A-63-78067 and JP-A-63-246396
According to the method described in the publication, monoclonal antibody JK-199 (immunoglobulin class IgG2a) against human type IV collagen was obtained from splenocytes obtained from BALB/C mice immunized with human type IV collagen and mouse myeloma cells SP2/O. The producing mouse hybridoma cells were formed and then selected to become the JK199 strain.
By subculturing the JK199 strain while gradually decreasing the concentration of serum added to the medium, the JK199 strain was finally grown in serum-free medium ASF104.
It was possible to acclimate to the culture medium (manufactured by Ajinomoto Co.). Example 2 Effect of culture temperature on antibody yield JK199 strain stored in a liquid nitrogen cell preserver was thawed.
The cells were placed in a 75 cm2 tissue culture flask (Costar) containing 50 mL of ASF104 medium supplemented with 0.3% polypeptone S (Daigo Nutrient Chemical Co., Ltd.) so that the cell concentration was approximately 105 cells/ml. The cells were inoculated and cultured stationary in a carbon dioxide gas culture device in which the temperature was maintained at 37° C. and the carbon dioxide gas concentration was maintained at 5%. After culturing for 3 days, this seed culture was inoculated into eight 75 cm2 tissue culture flasks containing 45 mL of the above medium with 5 mL each, and the culture temperature was maintained at 28 °C, 31 °C, 34 °C, 37 °C, and 40 °C, respectively. Two cells each were placed and cultured in a carbon dioxide culture device. The carbon dioxide concentration in the apparatus was all set to 5%. After culturing for 14 days, the total number of cells in the culture solution was counted using a hemocytometer. The antibody concentration in the culture medium was determined using a microplate coated with human type IV collagen, a biotinylated anti-mouse IgG2
It was measured by an enzyme-labeled immunoassay method using an a antibody, avidin peroxidase, and a chromogenic substrate. Table 1 shows the culture results controlled at each culture temperature. The antibody concentration is expressed as a relative value with the culture temperature at 37°C set as 100.

【0011】[0011]

【表1】[Table 1]

【0012】実施例3  抗体収量に対する培養器内の
炭酸ガス濃度の影響 液体窒素細胞保存器中で保存していた JK199株を
解凍し、この細胞をASF104培地にポリペプトンS
(大五栄養化学社製)を0.3%濃度添加した培地50
mLを入れた75cm2 組織培養フラスコ(コースタ
ー社)に細胞濃度が約105 個/mlとなるように接
種し、温度を37℃、炭酸ガス濃度を5%に維持した炭
酸ガス培養装置内で静置培養した。3日間培養後、この
種培養物を上記培地45mLを入れた75cm2 組織
培養フラスコ10個にそれぞれ5mLずつ接種し、炭酸
ガス濃度をそれぞれ1%、3%、5%、7%、9%に維
持した炭酸ガス培養装置内に2個ずつ静置して培養した
。培養温度はすべて37℃とした。14日間培養後、実
施例2と同様の方法により培養物中の細胞数および抗体
濃度を測定した。各培養温度での培養結果を表2に示す
。抗体濃度は炭酸ガス濃度が5%の場合を 100とし
た相対値で示す。
Example 3 Effect of carbon dioxide concentration in culture vessel on antibody yield The JK199 strain stored in a liquid nitrogen cell preserver was thawed, and the cells were transferred to ASF104 medium with polypeptone S.
Medium 50 supplemented with 0.3% concentration of (manufactured by Daigo Nutrient Chemical Co., Ltd.)
mL into a 75 cm2 tissue culture flask (Costar) at a cell concentration of approximately 105 cells/ml, and let stand in a carbon dioxide gas culture device maintained at a temperature of 37°C and a carbon dioxide gas concentration of 5%. Cultured. After culturing for 3 days, this seed culture was inoculated into 10 75 cm2 tissue culture flasks containing 45 mL of the above medium, 5 mL each, and the carbon dioxide concentration was maintained at 1%, 3%, 5%, 7%, and 9%, respectively. Two cells each were placed and cultured in a carbon dioxide culture device. The culture temperature was 37°C in all cases. After culturing for 14 days, the number of cells and antibody concentration in the culture were measured by the same method as in Example 2. Table 2 shows the culture results at each culture temperature. The antibody concentration is expressed as a relative value, with the carbon dioxide concentration being 5% as 100.

【0013】[0013]

【表2】[Table 2]

【0014】実施例4  マルチトレイを用いた培養液
体窒素細胞保存器中で保存していた JK199株を解
凍し、この細胞をASF104培地にポリペプトンSを
0.3%濃度添加した培地50mLを入れた75cm2
 組織培養フラスコ3個に、細胞濃度が約105 個/
mlとなるようにそれぞれ接種し、培養温度を37℃、
炭酸ガス濃度を5%に維持した炭酸ガス培養装置内で静
置培養した。3日間培養後、上記培地1650mLを入
れたマルチトレイ(商品名セルファクトリー、10段、
ヌンク社)にこの種培養物(総量 150mL) を接
種し、培養温度を34℃、培養装置内炭酸ガス濃度を3
%に維持した炭酸ガス培養装置で静置培養した。 14日間培養後、培養液から遠心分離で細胞を除去し、
水酸化ナトリウムでpHを8.0に調整した培養上澄を
、0.1Mりん酸緩衝液(pH8.0)で平衡化したプ
ロテインAセファロース(ファルマシア社)アフィニテ
ィカラムに通して抗体をプロテインAに結合させた。0
.1Mりん酸緩衝液(pH8.0)でカラムを十分洗浄
後、8M尿素水溶液(pH7.0)で抗体を溶離させ、
透析膜を用いて0.1Mりん酸緩衝液(pH7.0)に
対して透析を行ない、精製抗体を得た。280nm の
吸光度(OD280) から精製抗体濃度を算出した。
Example 4 Culture using a multi-tray The JK199 strain stored in a liquid nitrogen cell preserver was thawed, and the cells were placed in 50 mL of ASF104 medium supplemented with polypeptone S at a concentration of 0.3%. 75cm2
In three tissue culture flasks, the cell concentration was approximately 105 cells/
ml of each, and the culture temperature was set at 37°C.
The cells were statically cultured in a carbon dioxide culture device in which the carbon dioxide concentration was maintained at 5%. After culturing for 3 days, a multi-tray containing 1650 mL of the above medium (trade name: Cell Factory, 10 stages,
This seed culture (total volume: 150 mL) was inoculated into a Nunc Co., Ltd., culture temperature was 34℃, and the carbon dioxide concentration in the culture device was 34℃.
The cells were statically cultured in a carbon dioxide culture device maintained at %. After culturing for 14 days, cells were removed from the culture medium by centrifugation,
The culture supernatant, whose pH was adjusted to 8.0 with sodium hydroxide, was passed through a Protein A Sepharose (Pharmacia) affinity column equilibrated with 0.1 M phosphate buffer (pH 8.0) to convert the antibody to Protein A. Combined. 0
.. After thoroughly washing the column with 1M phosphate buffer (pH 8.0), the antibody was eluted with 8M urea aqueous solution (pH 7.0).
Dialysis was performed against 0.1M phosphate buffer (pH 7.0) using a dialysis membrane to obtain a purified antibody. The purified antibody concentration was calculated from the absorbance at 280 nm (OD280).

【0015】比較例として、培養温度を37℃、培養装
置内炭酸ガス濃度を5%に維持した炭酸ガス培養装置で
マルチトレイを用いた培養を行い、14日間培養後、上
記と同様の方法で培養液から抗体を回収した。表3から
明らかなように、培養温度を34℃、培養装置内炭酸ガ
ス濃度を3%に維持すると、比較例に比べて抗体収量は
飛躍的に増大して、培養液1リットル当り 150mg
に達した。
As a comparative example, culture was carried out using a multi-tray in a carbon dioxide gas culture device in which the culture temperature was maintained at 37° C. and the carbon dioxide gas concentration in the culture device was maintained at 5%, and after culturing for 14 days, the same method as above was carried out. Antibodies were collected from the culture solution. As is clear from Table 3, when the culture temperature was maintained at 34°C and the carbon dioxide concentration in the culture apparatus was maintained at 3%, the antibody yield increased dramatically compared to the comparative example, reaching 150 mg per liter of culture solution.
reached.

【0016】[0016]

【表3】[Table 3]

【0017】[0017]

【発明の効果】本発明によれば、従来画一的に設定され
ていた培養温度である37℃を、単にそれより低い温度
に制御することによって飛躍的に抗体収量を向上させた
抗体の製造方法が提供される。
Effects of the Invention According to the present invention, antibodies can be produced in which the antibody yield is dramatically improved by simply controlling the culture temperature of 37°C, which has conventionally been uniformly set, to a lower temperature. A method is provided.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】  抗体産生能を有する細胞を栄養培地で
培養して培養物から抗体を回収する抗体の製造方法であ
って、培養温度を29℃から36℃の範囲内に制御する
ことを含んでなる方法。
Claim 1: A method for producing antibodies, which comprises culturing cells capable of producing antibodies in a nutrient medium and recovering antibodies from the culture, the method comprising controlling the culture temperature within the range of 29°C to 36°C. How to become.
JP3064843A 1991-03-28 1991-03-28 Produciton of antibody Withdrawn JPH04299992A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3064843A JPH04299992A (en) 1991-03-28 1991-03-28 Produciton of antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3064843A JPH04299992A (en) 1991-03-28 1991-03-28 Produciton of antibody

Publications (1)

Publication Number Publication Date
JPH04299992A true JPH04299992A (en) 1992-10-23

Family

ID=13269914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3064843A Withdrawn JPH04299992A (en) 1991-03-28 1991-03-28 Produciton of antibody

Country Status (1)

Country Link
JP (1) JPH04299992A (en)

Similar Documents

Publication Publication Date Title
RU1831500C (en) Process of reducing a heterogeneity of secretory monoclonal antibodies
EP0014519B1 (en) Cell lines, process for preparing them and process for producing antibodies
Duff Microencapsulation technology: a novel method for monoclonal antibody production
EP3019528A1 (en) Improved process for production of monoclonal antibodies
JP2925181B2 (en) Methods for reducing the heterogeneity of monoclonal antibodies
Voigt et al. Hybridoma cell growth and anti-neuroblastoma monoclonal antibody production in spinner flasks using a protein-free medium with microcarriers
AU2017345387A1 (en) Continuous process for reducing heterogeneity of therapeutic protein
JPH0588116B2 (en)
JP2021516971A (en) Biopolymer production methods, production modules, and use in production by stepwise fractionation in upstream production processes
CN109265539A (en) Utilize the method for hybridoma production monoclonal antibody and its monoclonal antibody of production
US4939082A (en) Process and monoclonal antibody for the specific determination of pancreas alpha-amylase in the presence of saliva alpha-amylase
JPH04299992A (en) Produciton of antibody
JPH05508546A (en) Purification of Erwinia-L-asparaginase
CN114276456B (en) Hybridoma cell strain secreting mouse anti-human IgG monoclonal antibody, monoclonal antibody secreted by hybridoma cell strain and application of hybridoma cell strain
Fong et al. Optimization of monoclonal antibody production: combined effects of potassium acetate and perfusion in a stirred tank bioreactor
JPH0630619B2 (en) Monoclonal anti-human granulocyte colony-stimulating factor antibody
US5688919A (en) Process for the purification of factor XIII, monoclonal antibodies against factor XIIIA, the preparation and use thereof
JP2627076B2 (en) Anti-tetanus toxin human monoclonal antibody, neutralizing agent for tetanus toxin using the same, and hybridoma producing human monoclonal antibody
JP3741647B2 (en) Anti-fucoidan antibody
Munster et al. A high density culture system for the in-vitro production of human and mouse monoclonal antibodies
Jacobin et al. Production of a human monoclonal IgM directed against human cardiac myosin in a hollow-fiber bioreactor for membrane anion exchange chromatography one-step purification
Goergen et al. Comparison of specific rates of hybridoma growth and metabolism in batch and continuous cultures
CN105925539B (en) Method for preparing monoclonal ascites antibody
RU2319743C1 (en) Strain of hybrid cultured mammalian cells mus musculus as producer of monoclonal antibodies to hypoglycosidated and deglycosidated isoforms of tumor-associated human antigen muc i
JPS62210984A (en) Separation and purification of canine c-reactive protein using hybridoma producing monoclonal antibody against canine c-reactive protein and said antibody

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 19980514